Discovery of new gene mutation in schizophrenia offers target for drug therapies

Feb 23, 2011

In a major advance for schizophrenia research, an international team of scientists led by the University of California, San Diego School of Medicine and involving Trinity College Dublin researchers has identified a gene mutation strongly linked to schizophrenia that may be an important new target for the development of drug therapies. The findings are just published in the online issue of the journal Nature.

Schizophrenia is a chronic, severe and disabling brain disorder, with symptoms that include hallucinations, delusions and thought disorder. is believed to be caused by environmental and , most notably the latter: the illness occurs in 1% of the general population, or 10 % of people who have a first-degree relative with the disorder, such as a parent or sibling. Current therapies are only partially effective with little progress being made in identifying effective new treatments over several decades.

In the last three years researchers have discovered that rare mutations at many locations in the human resulted in significantly higher risk of schizophrenia. These mutations consisted of copy number variants or CNVs −a type of genetic variation in which the number of copies of a gene differs between individuals. The findings were the first conclusive evidence that rare mutations can cause schizophrenia, but this did not identify the specific genes involved.

Professor Aiden Corvin of the Psychosis Research Group at Trinity College Dublin, funded by Science Foundation Ireland and the Wellcome Trust, and an author on this paper, describes that the latest study goes substantially further.

Researchers scanned for CNVs in the genomes of 8,290 individuals with diagnosed cases of schizophrenia and 7,431 healthy controls. The study confirmed CNVs identified in earlier studies, but uncovered an important new finding: duplications at the tip of chromosome 7q were detected in individuals with schizophrenia at a rate 14 times higher than in healthy individuals. These duplications impact a gene coding for the brain receptor VIPR2.

Formally known as the Vasoactive Intestinal Peptide Receptor 2, VIPR2 is expressed in the nervous system, including in the brain, blood vessels and gastrointestinal tract. Previous studies have shown that VIPR2 helps to regulate the formation and activity of neurons in the brain. In mice, VIPR2 also has been found to play important roles in behavioral processes, including learning and timing of daily activity. The study next measured expression of the VIPR2 gene in blood cells from patients, they found that individuals with mutations had greater expression of VIPR2 and greater activity of the receptor.

"This suggests that the mutations increase signaling in the Vasoactive Intestinal Peptide pathway," says Professor Corvin. "We know that this activity can be modulated by synthetic peptides (compounds where amino acids are linked together) and the next step is to see if these compounds have a therapeutic effect in mice or in cultured human cells that carry the VIPR2 ."

Explore further: Genetic mutation found to cause ovarian insufficiency in women under 40

add to favorites email to friend print save as pdf

Related Stories

Schizophrenia gene mutation found; target for new drugs

Feb 02, 2011

In a major advance for schizophrenia research, an international team of scientists, led by Jonathan Sebat, PhD, assistant professor of psychiatry and cellular and molecular medicine at the University of California, San Diego ...

Gene with possible link to schizophrenia identified

Feb 27, 2008

Virginia Commonwealth University researchers have identified a gene associated with schizophrenia that could provide further insight about the functional changes that occur on the molecular level in individuals who suffer ...

Scientists find gene linked to schizophrenia

Apr 12, 2010

An international study led by Université de Montréal scientists suggests that gene mutations may predispose some individuals to schizophrenia and provides new clues about the causes of this ambiguous disorder. ...

Genes found for schizophrenia are involved in brain signaling

May 10, 2010

By analyzing the genomes of patients with schizophrenia, genetics researchers have discovered numerous copy number variations—deletions or duplications of DNA sequences—that increase the risk of developing schizophrenia. ...

Recommended for you

Nationwide project paves way for clinical genetic diagnosis

Dec 16, 2014

The first nationwide project to genetically diagnose rare diseases will pave the way for translating advances in genomics into patient care in the NHS. Deciphering Developmental Disorders (DDD), a collaboration between the ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.